Acute In Vitro and In Vivo Effects of Dexamethasone in the Vocal Folds: a Pilot Study
- 1 November 2022
- journal article
- research article
- Published by Wiley in The Laryngoscope
- Vol. 133 (9) , 2264-2270
Abstract
Objectives/Hypothesis: Glucocorticoids (GC)s are commonly employed to treat vocal fold (VF) pathologies. However, VF atrophy has been associated with intracordal GC injections. Dexamethasone‐induced skeletal muscle atrophy is well‐documented in other tissues and believed to be mediated by increased muscle proteolysis via upregulation of Muscle Ring Finger (MuRF)‐1 and Atrogin‐1. Mechanisms of dexamethasone‐mediated VF atrophy have not been described. This pilot study employed in vitro and in vivo models to investigate the effects of dexamethasone on VF epithelium, thyroarytenoid (TA) muscle, and TA‐derived myoblasts. We hypothesized that dexamethasone will increase atrophy‐associated gene expression in TA muscle and myoblasts and decrease TA muscle fiber size and epithelial thickness.Study Design: In vitro, pre‐clinical.Methods: TA myoblasts were isolated from a female Sprague–Dawley rat and treated with 1 μM dexamethasone for 24‐h. In vivo, 15 New Zealand white rabbits were randomly assigned to three treatment groups: (1) bilateral intracordal injection of 40 μL dexamethasone (10 mg/ml; n = 5), (2) volume‐matched saline (n = 5), and (3) untreated controls (n = 5). Larynges were harvested 7‐days post‐injection. Across in vivo and in vitro experimentation, MuRF‐1 and Atrogin‐1 mRNA expression were measured via RT‐qPCR. TA muscle fiber cross‐sectional area (CSA) and epithelial thickness were also quantified in vivo.Results: Dexamethasone increased MuRF‐1 gene expression in TA myoblasts. Dexamethasone injection, however, did not alter atrophy‐associated gene expression, TA CSA, or epithelial thickness in vivo.Conclusion: Dexamethasone increased atrogene expression in TA myoblasts, providing foundational insight into GC induced atrophic gene transcription. Repeated dexamethasone injections may be required to elicit atrophy in vivo.Level of Evidence: NA Laryngoscope, 133:2264–2270, 2023Keywords
Funding Information
- National Center for Advancing Translational Sciences (TL1‐TR001858)
- National Institute on Deafness and Other Communication Disorders (R01DC015405, R01DC017397)
This publication has 55 references indexed in Scilit:
- Oxidative damage and myofiber degeneration in the gastrocnemius of patients with peripheral arterial diseaseJournal of Translational Medicine, 2013
- Muscle sparing in muscle RING finger 1 null mice: response to synthetic glucocorticoidsThe Journal of Physiology, 2011
- Molecular mechanisms of glucocorticoids action: implications for treatment of rhinosinusitis and nasal polyposisEuropean Archives of Oto-Rhino-Laryngology, 2010
- Activation of RXR and RAR signaling promotes myogenic differentiation of myoblastic C2C12 cellsDifferentiation, 2009
- The Wound Healing Process: An Overview of the Cellular and Molecular MechanismsJournal of International Medical Research, 2009
- Regulation of Signaling Pathways Downstream of IGF-I/Insulin by Androgen in Skeletal Muscle of Glucocorticoid-Treated RatsJournal of Trauma: Injury, Infection & Critical Care, 2009
- Dexamethasone and corticosterone induce similar, but not identical, muscle wasting responses in cultured L6 and C2C12 myotubesJournal of Cellular Biochemistry, 2008
- Expression and activity of C/EBPβ and δ are upregulated by dexamethasone in skeletal muscleJournal of Cellular Physiology, 2005
- The IGF-1/PI3K/Akt Pathway Prevents Expression of Muscle Atrophy-Induced Ubiquitin Ligases by Inhibiting FOXO Transcription FactorsMolecular Cell, 2004
- The muscular dystrophiesThe Lancet, 2002